These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 10091153

  • 1. Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine.
    De Sanctis V, Stea S, Savarino L, Scialpi V, Traina GC, Chiarelli GM, Sprocati M, Govoni R, Pezzoli D, Gamberini R, Rigolin F.
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():827-33. PubMed ID: 10091153
    [Abstract] [Full Text] [Related]

  • 2. Desferrioxamine-induced long bone changes in thalassaemic patients - radiographic features, prevalence and relations with growth.
    Chan YL, Li CK, Pang LM, Chik KW.
    Clin Radiol; 2000 Aug; 55(8):610-4. PubMed ID: 10964732
    [Abstract] [Full Text] [Related]

  • 3. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
    Cavallo L, Gurrado R, Zecchino C, Manolo F, De Sanctis V, Cisternino M, Caruso-Nicoletti M, Galati M.
    J Pediatr Endocrinol Metab; 1998 Aug; 11 Suppl 3():845-9. PubMed ID: 10091155
    [Abstract] [Full Text] [Related]

  • 4. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia.
    Chan YL, Pang LM, Chik KW, Cheng JC, Li CK.
    Pediatr Radiol; 2002 Jul; 32(7):492-7. PubMed ID: 12107582
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of skeletal dysplasia in thalassaemia major.
    Naselli A, Vignolo M, Di Battista E, Garzia P, Forni GL, Traverso T, Aicardi G.
    J Pediatr Endocrinol Metab; 1998 Jul; 11 Suppl 3():817-25. PubMed ID: 10091152
    [Abstract] [Full Text] [Related]

  • 6. Reduced insulin growth factor I concentrations in iron-overloaded beta thalassaemic patients with normal growth hormone secretion and liver function.
    Karamifar H, Karimi M, Amirhakimi G, Sharbatialaei M, De Sanctis V.
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():256-8. PubMed ID: 16462706
    [Abstract] [Full Text] [Related]

  • 7. Deferoxamine-induced bone dysplasia in the distal femur and patella of pediatric patients and young adults: MR imaging appearance.
    Chan Y, Li C, Chu WC, Pang L, Cheng JC, Chik KW.
    AJR Am J Roentgenol; 2000 Dec; 175(6):1561-6. PubMed ID: 11090375
    [Abstract] [Full Text] [Related]

  • 8. Growth failure and bone lesions due to desferrioxamine in thalassaemic patients.
    Caruso-Nicoletti M, Di Bella D, Pizzarelli G, Leonardi C, Sciuto C, Coco M, Di Gregorio F.
    J Pediatr Endocrinol Metab; 1998 Dec; 11 Suppl 3():957-60. PubMed ID: 10091171
    [No Abstract] [Full Text] [Related]

  • 9. Osteochondrodystrophic lesions in chelated thalassemic patients: an histological analysis.
    de Sanctis V, Stea S, Savarino L, Granchi D, Visentin M, Sprocati M, Govoni R, Pizzoferrato A.
    Calcif Tissue Int; 2000 Aug; 67(2):134-40. PubMed ID: 10920218
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of growth hormone therapy for patients with skeletal dysplasia.
    Kanazawa H, Tanaka H, Inoue M, Yamanaka Y, Namba N, Seino Y.
    J Bone Miner Metab; 2003 Aug; 21(5):307-10. PubMed ID: 12928832
    [Abstract] [Full Text] [Related]

  • 11. Short stature and body proportion in thalassaemia.
    Caruso-Nicoletti M, De Sanctis V, Capra M, Cardinale G, Cuccia L, Di Gregorio F, Filosa A, Galati MC, Lauriola A, Malizia R, Mangiagli A, Massolo F, Mastrangelo C, Meo A, Messina MF, Ponzi G, Raiola G, Ruggiero L, Tamborino G, Saviano A.
    J Pediatr Endocrinol Metab; 1998 Aug; 11 Suppl 3():811-6. PubMed ID: 10091151
    [Abstract] [Full Text] [Related]

  • 12. Growth hormone secretion in adult patients with thalassaemia.
    La Rosa C, De Sanctis V, Mangiagli A, Mancuso M, Guardabasso V, Galati MC, Caruso-Nicoletti M.
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):667-71. PubMed ID: 15943827
    [Abstract] [Full Text] [Related]

  • 13. [Long-term follow-up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity].
    Mangiagli A, De Sanctis V, Campisi S, Di Silvestro G, Urso L.
    Minerva Pediatr; 2000 Apr; 52(4):235-41. PubMed ID: 11995208
    [Abstract] [Full Text] [Related]

  • 14. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 15. Growth hormone deficiency (GHD) in adult thalassaemic patients.
    Scacchi M, Danesi L, Cattaneo A, Valassi E, Pecori Giraldi F, Argento C, D'Angelo E, Mirra N, Carnelli V, Zanaboni L, Cappellini MD, Cavagnini F.
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):790-5. PubMed ID: 17608814
    [Abstract] [Full Text] [Related]

  • 16. Growth and puberty and its management in thalassaemia.
    De Sanctis V.
    Horm Res; 2002 Nov; 58 Suppl 1():72-9. PubMed ID: 12373018
    [Abstract] [Full Text] [Related]

  • 17. Deferoxamine-induced dysplasia of the knee: sonographic features and diagnostic performance compared with magnetic resonance imaging.
    Chan YL, Chu CW, Chik KW, Pang LM, Shing MK, Li CK.
    J Ultrasound Med; 2001 Jul; 20(7):723-8. PubMed ID: 11444730
    [Abstract] [Full Text] [Related]

  • 18. A histological and ultrastructural study of the iliac crest apophysis in Legg-Calve-Perthes disease.
    Kitoh H, Kitakoji T, Kawasumi M, Ishiguro N.
    J Pediatr Orthop; 2008 Jun; 28(4):435-9. PubMed ID: 18520280
    [Abstract] [Full Text] [Related]

  • 19. MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major.
    Miller TT, Caldwell G, Kaye JJ, Arkin S, Burke S, Brill PW.
    Pediatr Radiol; 1993 Jun; 23(7):523-4. PubMed ID: 8309753
    [Abstract] [Full Text] [Related]

  • 20. Growth hormone (GH) deficiency in patients with beta-thalassemia major and the efficacy of recombinant GH treatment.
    Wu KH, Tsai FJ, Peng CT.
    Ann Hematol; 2003 Oct; 82(10):637-40. PubMed ID: 12898188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.